Review
Pharmacology & Pharmacy
Athanasia K. Papazafiropoulou, Andreas Melidonis, Stavros Antonopoulos
Summary: In recent years, research has shown that GLP-1 receptor agonists and SGLT2 inhibitors not only improve glycemic control in diabetic patients, but also have positive effects on cardiovascular risk factors and weight. These drugs may also have benefits for non-diabetic patients.
CURRENT PHARMACEUTICAL DESIGN
(2021)
Review
Endocrinology & Metabolism
Christophe E. M. De Block, Eveline Dirinck, Ann Verhaegen, Luc F. Van Gaal
Summary: Glucagon-like peptide-1 receptor agonists and dual GLP-1/glucose-dependent insulinotropic peptide RA tirzepatide have expanded the population of individuals reaching HbA1c and weight targets, showing potential therapeutic benefits. However, further research is needed to determine whether this will lead to improved cardiovascular outcomes and impact treatment guidelines.
DIABETES OBESITY & METABOLISM
(2022)
Review
Endocrinology & Metabolism
Ronald M. Goldenberg, Jeremy D. Gilbert, Priya Manjoo, Sue D. Pedersen, Vincent C. Woo, Julie A. Lovshin
Summary: Type 2 diabetes, obesity, and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis have mutual causalities and there are medications being developed that may offer clinical benefits to all three conditions. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have shown efficacy in managing type 2 diabetes and obesity, and exploring higher doses or developing novel co-agonists is of great interest.
Article
Endocrinology & Metabolism
Giulia Di Dalmazi, Sara Coluzzi, Maria Pompea Antonia Baldassarre, Amr Ghit, Giusi Graziano, Maria Chiara Rossi, Beatrice Ciappini, Marica Milo, Federica Carrieri, Antonio Nicolucci, Agostino Consoli, Gloria Formoso
Summary: This study aims to evaluate the effectiveness and tolerability of once-weekly glucagon-like peptide receptor agonists (OW GLP-1RAs) and to assess the clinical benefits of switching from one GLP-1RA to another in routine clinical settings. The study found that semaglutide showed the largest improvement in HbA1c and body weight.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Review
Cardiac & Cardiovascular Systems
Nikolaus Marx, Mansoor Husain, Michael Lehrke, Subodh Verma, Naveed Sattar
Summary: Multiple large cardiovascular outcome trials have shown that SGLT2 inhibitors and GLP-1 receptor agonists significantly reduce cardiovascular disease risk in patients with type 2 diabetes, including major adverse cardiovascular events and heart failure. These drugs have received strong recommendations in diabetes and cardiology guidelines, but their usage remains low.
Article
Cardiac & Cardiovascular Systems
Dario Giugliano, Lorenzo Scappaticcio, Miriam Longo, Paola Caruso, Maria Ida Maiorino, Giuseppe Bellastella, Antonio Ceriello, Paolo Chiodini, Katherine Esposito
Summary: Glucagon-like peptide-1 receptor agonists have significant benefits on cardiovascular and renal outcomes in patients with type 2 diabetes, including reducing major cardiovascular events, hospitalization for heart failure, all-cause mortality, and the incidence of macroalbuminuria.
CARDIOVASCULAR DIABETOLOGY
(2021)
Review
Endocrinology & Metabolism
Daniel Yuan, Harman Sharma, Anirudh Krishnan, Venkat N. Vangaveti, Usman H. Malabu
Summary: This study aimed to determine the effect of GLP-1 receptor agonists on albuminuria in adult patients with T2DM. The meta-analysis of numerous studies showed that the use of GLP-1RAs is associated with a significant reduction in albuminuria in adult patients with T2DM.
DIABETES OBESITY & METABOLISM
(2022)
Article
Multidisciplinary Sciences
Emilie H. Zobel, Rasmus S. Ripa, Bernt J. von Scholten, Viktor Rotbain Curovic, Andreas Kjaer, Tine W. Hansen, Peter Rossing, Joachim Storling
Summary: Liraglutide has been found to exert anti-inflammatory effects in the peripheral blood mononuclear cells of individuals with type 2 diabetes, with no significant presence of GLP-1 receptor expression. Further research is needed to clarify the indirect effects of liraglutide on PBMC gene expression and establish the anti-inflammatory potential of GLP-1 receptor agonists.
SCIENTIFIC REPORTS
(2021)
Article
Endocrinology & Metabolism
Katrina B. Dietsche, Sheela N. Magge, Sydney A. Dixon, Faith S. Davis, Andrea Krenek, Aruba Chowdhury, Lilian Mabundo, Michael Stagliano, Amber B. Courville, Shanna Yang, Sara Turner, Hongyi Cai, Kannan Kasturi, Arthur S. Sherman, Joon Ha, Eileen Shouppe, Mary Walter, Peter J. Walter, Kong Y. Chen, Robert J. Brychta, Cody Peer, Yi Zeng, William Figg, Fran Cogen, D. Elizabeth Estrada, Shaji Chacko, Stephanie T. Chung
Summary: This study evaluated the glucose-lowering mechanisms of metformin and liraglutide in African American youth with youth-onset type 2 diabetes. The results showed that both metformin and liraglutide improved glycemic control but did not suppress high rates of gluconeogenesis. Novel therapies targeting beta-cell function and elevated rates of gluconeogenesis are needed for youth-onset type 2 diabetes.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2023)
Article
Endocrinology & Metabolism
Keiu Heinla, Eero Vasar, Ingrid Reppo, Tuuli Sedman, Vallo Volke
Summary: The study investigates the effect of GLP-1RAs on growth hormone (GH) secretion. Two separate clinical trials were conducted to examine the impact of short-acting and long-acting GLP-1RAs on GH levels. The findings suggest that GLP-1RAs may increase GH secretion, indicating a potential novel mechanism for regulating GH.
Article
Endocrinology & Metabolism
Marja-Riitta Taskinen, Elias Bjornson, Niina Matikainen, Sanni Soderlund, Kirsi H. Pietilainen, Mari Ainola, Antti Hakkarainen, Nina Lundbom, Johannes Fuchs, Annika Thorsell, Linda Andersson, Martin Adiels, Chris J. Packard, Jan Boren
Summary: In subjects with type 2 diabetes, liraglutide demonstrated positive effects on postprandial apoB48 metabolism, including reducing apoB48 synthesis, improving chylomicron size, and decreasing direct clearance of chylomicrons, as well as lowering VLDL1-triglyceride secretion. The impact of liraglutide on insulin sensitivity altered certain associations related to chylomicron-apoB48 production and particle size, ultimately contributing to decreased generation of remnant lipoproteins.
DIABETES OBESITY & METABOLISM
(2021)
Review
Endocrinology & Metabolism
Chloe Wong, Ming Hui Lee, Clyve Yu Leon Yaow, Yip Han Chin, Xin Lei Goh, Cheng Han Ng, Amanda Yuan Ling Lim, Mark Dhinesh Muthiah, Chin Meng Khoo
Summary: This meta-analysis examined the efficacy of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus. Results showed significant improvements in hepatic fat content, liver biochemistry, body composition, glucose parameters, lipid parameters, insulin sensitivity, and inflammatory markers following treatment with glucagon-like peptide-1 receptor agonists. Glucagon-like peptide-1 receptor agonists were also found to significantly decrease hepatic fat content compared to other treatments, showing promise in improving both diabetes and non-alcoholic fatty liver disease phenotype.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Article
Endocrinology & Metabolism
Chih-Yiu Tsai, Hsiu-Chen Lu, Yu-Hsien Chou, Po-Yu Liu, Hsin-Yun Chen, Meng-Chuan Huang, Chia-Hung Lin, Chi-Neu Tsai
Summary: This pilot study aimed to identify microbial signatures associated with glycemic responses to GLP-1 RA treatment in patients with T2D. The results showed that the microbial diversity differed significantly between responders and non-responders, and specific microbial features were correlated with glycemic reduction. These findings indicate that gut microbiota may play a role in the heterogeneity of responses to GLP-1 RA treatment in T2D.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Clinical Neurology
Tushar Issar, Natalie C. G. Kwai, Ann M. Poynten, Ria Arnold, Kerry-Lee Milner, Arun V. Krishnan
Summary: This study assessed the effect of exenatide, DPP-IV inhibitors, and SGLT-2 inhibitors on peripheral nerve excitability in patients with type 2 diabetes. Patients treated with exenatide showed improvements in nerve excitability, whereas those receiving DPP-IV or SGLT-2 inhibitors exhibited abnormalities in nerve function.
CLINICAL NEUROPHYSIOLOGY
(2021)
Review
Endocrinology & Metabolism
Mainak Banerjee, Rimesh Pal, Satinath Mukhopadhyay, Kirthana Nair
Summary: GLP-1RAs can reduce the risk of ischemic cerebrovascular events in patients with type 2 diabetes, especially with longer treatment duration. The effectiveness of the drug can vary based on individual baseline kidney function and duration of diabetes.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2023)
Article
Endocrinology & Metabolism
Mariano Sanz, Antonio Ceriello, Martin Buysschaert, Iain Chapple, Ryan T. Demmer, Filippo Graziani, David Herrera, Soren Jepsen, Luca Lione, Phoebus Madianos, Manu Mathur, Eduard Montanya, Lior Shapira, Maurizio Tonetti, Daniel Vegh
DIABETES RESEARCH AND CLINICAL PRACTICE
(2018)
Article
Cell Biology
Sergi Soriano, Manuel Castellano-Munoz, Alex Rafacho, Paloma Alonso-Magdalena, Laura Marroqui, Antonia Ruiz-Pino, Eva Bru-Tari, Beatriz Merino, Esperanza Irles, Melisa Bello-Perez, Pau Iborra, Sabrina Villar-Pazos, Jean F. Vettorazzi, Eduard Montanya, Raul M. Luque, Angel Nadal, Ivan Quesada
MOLECULAR AND CELLULAR ENDOCRINOLOGY
(2019)
Article
Oncology
Milana Bergamino, Antonio J. Rullan, Maria Saigi, Inmaculada Peiro, Eduard Montanya, Ramon Palmero, Jose Carlos Ruffinelli, Arturo Navarro, Maria Dolores Arnaiz, Isabel Brao, Samantha Aso, Susana Padrones, Felipe Cardenal, Ernest Nadal
Article
Multidisciplinary Sciences
Sandra Marin-Canas, Elisabet Estilles, Laura Llado, Patricia San Jose, Montserrat Nacher, Noelia Tellez, Eduard Montanya
Article
Endocrinology & Metabolism
Helena W. Rodbard, Julio Rosenstock, Luis H. Canani, Chaicharn Deerochanawong, Janusz Gumprecht, Soren Ostergaard Lindberg, Ildiko Lingvay, Anette Luther Sondergaard, Marianne Bach Treppendahl, Eduard Montanya
Article
Dentistry, Oral Surgery & Medicine
Eduardo Montero, Martina La Rosa, Eduard Montanya, Alfonso L. Calle-Pascual, Robert J. Genco, Mariano Sanz, David Herrera
JOURNAL OF PERIODONTAL RESEARCH
(2020)
Article
Multidisciplinary Sciences
G. Rojo-Martinez, S. Valdes, F. Soriguer, J. Vendrell, I Urrutia, V Perez, E. Ortega, P. Ocon, E. Montanya, E. Menendez, A. Lago-Sampedro, T. Gonzalez-Frutos, R. Gomis, A. Goday, S. Garcia-Serrano, E. Garcia-Escobar, J. L. Galan-Garcia, C. Castell, R. Badia-Guillen, G. Aguilera-Venegas, J. Girbes, S. Gaztambide, J. Franch-Nadal, E. Delgado, F. J. Chaves, L. Castano, A. Calle-Pascual
SCIENTIFIC REPORTS
(2020)
Article
Multidisciplinary Sciences
E. Garcia-Escobar, S. Valdes, F. Soriguer, J. Vendrell, I. M. Urrutia-Etxebarria, C. Maldonado-Araque, E. Ortega, P. Ocon, E. Montanya, E. Menendez, A. Lago-Sampedro, T. Gonzalez-Frutos, R. Gomis, A. Goday, S. Garcia-Serrano, J. L. Galan-Garcia, C. Castell, E. Bordiu, R. Badia, G. Aguilera-Venegas, J. Girbes, S. Gaztambide, E. Delgado, F. J. Chaves, L. Castano, A. Calle-Pascual, G. Rojo-Martinez, J. Franch-Nadal
Summary: The study found that a high FLI category was a significant independent risk factor for developing diabetes, even under normal blood sugar conditions. Additionally, including FLI categories in prediction models based on traditional T2DM risk factors significantly increased the predictive power of the models in the overall population.
SCIENTIFIC REPORTS
(2021)
Article
Health Care Sciences & Services
J. L. Lee, L. Foschini, S. Kumar, J. Juusola, J. Liska, M. Mercer, C. Tai, R. Buzzetti, M. Clement, X. Cos, L. Ji, N. Kanumilli, D. Kerr, E. Montanya, D. Mueller-Wieland, C. G. Ostenson, N. Skolnik, V. Woo, N. Burlet, M. Greenberg, S. I. Samson
Summary: In a 6-month intervention using an online health platform, the vaccination rate for influenza in people with self-reported diabetes was increased by 3.1% compared to the control group. Completion of intervention messages was associated with up to an 8% increase in vaccination rate. Leveraging new technology was effective in improving vaccination rates in high-risk populations such as PWD.
NPJ DIGITAL MEDICINE
(2021)
Article
Multidisciplinary Sciences
Viyey Doulatram-Gamgaram, Sergio Valdes, Cristina Maldonado-Araque, Ana Lago-Sampedro, Rocio Badia-Guillen, Eva Garcia-Escobar, Sara Garcia-Serrano, Marta Garcia-Vivanco, Juan Luis Garrido, Mark Richard Theobald, Victoria Gil, Fernando Martin-Llorente, Alfonso Calle-Pascual, Elena Bordiu, Luis Castano, Elias Delgado, Josep Franch-Nadal, F. Javier Chaves, Eduard Montanya, Jose Luis Galan-Garcia, Gabriel Aguilera-Venegas, Federico Soriguer, Gemma Rojo-Martinez
Summary: Exposure to air particulate matter is associated with an increased risk of hypertension, and the metabolic risks of air pollution should take into account the specific characteristics of each area. This study contributes to the assessment of the impact of particulate pollution on the incidence of hypertension in Spain.
SCIENTIFIC REPORTS
(2021)
Article
Endocrinology & Metabolism
Vanita R. Aroda, Robert Bauer, Erik Christiansen, Martin Haluzik, Klaus Kallenbach, Eduard Montanya, Julio Rosenstock, Juris J. Meier
Summary: Oral semaglutide demonstrated consistent efficacy in patients with type 2 diabetes across various patient characteristics, with better results seen in patients with higher baseline HbA1c levels. Compared to comparators, oral semaglutide had a higher incidence of gastrointestinal adverse events.
DIABETES OBESITY & METABOLISM
(2022)
Review
Cell Biology
Eva Tuduri, Sergi Soriano, Lucia Almagro, Eduard Montanya, Paloma Alonso-Magdalena, Angel Nadal, Ivan Quesada
Summary: This review summarizes the age-related alterations, adaptations, and failures of pancreatic β-cells at the molecular, morphological, and functional levels in both mice and humans. The findings suggest that changes in β-cell proliferation, apoptosis, and function with age may impact the development of type 2 diabetes.
AGEING RESEARCH REVIEWS
(2022)
Article
Endocrinology & Metabolism
Juris J. Meier, Lars Bardtrum, Alice Y. Y. Cheng, Brian Malling, Eduard Montanya, Lily Wagner, Richard E. Pratley
DIABETES OBESITY & METABOLISM
(2023)
Article
Endocrinology & Metabolism
Julio Rosenstock, Bertrand Cariou, Johanna Eliasson, Guillaume Frappin, Margit S. Kaltoft, Eduard Montanya, Filip K. Knop
Summary: The aim of this study was to assess the duration and likelihood of achieving HbA1c less than 7.0% in participants with type 2 diabetes using oral semaglutide compared to other medications.
DIABETES OBESITY & METABOLISM
(2023)
Article
Endocrinology & Metabolism
Martin Cuesta, Manuel Fuentes, Miguel Rubio, Elena Bordiu, Ana Barabash, Nuria Garcia de la Torre, Gemma Rojo-Martinez, Sergio Valdes, Federico Soriguer, Joan Josep Vendrell, Ines Maria Urrutia, Emilio Ortega, Eduard Montanya, Eldelmiro Menendez, Ana Lago-Sampedro, Ramon Gomis, Albert Goday, Conxa Castell, Rocio Badia-Guillen, Juan Girbes, Sonia Gaztambide, Josep Franch-Nadal, Elias Delgado Alvarez, Felipe Javier Chaves, Luis Castano, Alfonso L. Calle-Pascual
BMJ OPEN DIABETES RESEARCH & CARE
(2020)